LONDON (Reuters) – GlaxoSmithKline’s new shingles vaccine – a priority product as the company strives to improve its drugs line-up – has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show.
LONDON (Reuters) – GlaxoSmithKline’s new shingles vaccine – a priority product as the company strives to improve its drugs line-up – has won more than 90 percent U.S. market share just five months after its launch, prescription-tracking data show.